---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-008250"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2023-03-20T23:59:59+00:00"
generated_at: "2026-06-17T23:19:30.971584+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech FY2022 revenue $45.8M (+90% YoY); net loss $8.1M

## Summary
- Net revenue $45.8M vs $24.1M in 2021, a 90% increase; gross margin 86% vs 90%.
- Net loss $8.1M vs $8.0M in 2021; SG&A expenses rose to $46.0M from $28.1M.
- CellerateRX sold in over 700 facilities across 29 states; generated >$5M revenue in a single month.
- Entered partnership with InfuSystem for wound care; filed 510(k) for BIASURGE and Precision Healing Imager.
- Entered ATM sales agreement with Cantor Fitzgerald for stock offerings.

## SEC filing metadata
- accession: 0001493152-23-008250
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2023-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315223008250/0001493152-23-008250-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315223008250/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-008250
- JSON: https://secwatch.observer/filing/0001493152-23-008250.json
- Plain text: https://secwatch.observer/filing/0001493152-23-008250.txt

## Key facts
- Earnings Releases
  Sanara MedTech Inc. reported the quarter and year ended December 31, 2022 results: revenue $45.8 million.
  - Period: the quarter and year ended December 31, 2022
  - Revenue: $45.8 million
  - Result: reported results
  source text: for its Precision Healing Multispectral Imager Full Year 2022 Consolidated Financial Results ● Net Revenues. For the year ended December 31, 2022, we generated net revenues of $45.8 million compared to net revenues of $24.1 million for the year ended December 31, 2021, a 90% increase from the prior year. Our 2022 net revenues included $6.0 million of Scendia
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315223008250/0001493152-23-008250-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.